Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sapropterin Dihydrochloride + PD-1 Antibody in Advanced Pancreatic Cancer
NCT06396637Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2024
- Primary completion
- Apr 2025
- Modality
- Allosteric Modulators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of sapropterin in pancreatic ductal adenocarcinoma (PDAC), sponsored by Sun Yat-sen University. Started Apr 2024; status: recruiting.
02
Drugs
sapropterin
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06396637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06396637.